CoChat
Sign Up
Cited by 177Radiopharmaceutical Chemistry and ApplicationsChemical Reactions and IsotopesNuclear physics research studies

Actinium-225 in targeted alpha-particle therapeutic applications.

Open access
A. Scheinberg, David, R. McDevitt, Michael·2011·Current Radiopharmaceuticalse
DOI 10.2174/1874471011104040306PMC PMC5565267
Open this paper in CoChat — free account

Abstract

Alpha particle-emitting isotopes are being investigated in radioimmunotherapeutic applications because of their unparalleled cytotoxicity when targeted to cancer and their relative lack of toxicity towards untargeted normal tissue. Actinium- 225 has been developed into potent targeting drug constructs and is in clinical use against acute myelogenous leukemia. The key properties of the alpha particles generated by 225Ac are the following: i) limited range in tissue of a few cell diameters; ii) high linear energy transfer leading to dense radiation damage along each alpha track; iii) a 10 day halflife; and iv) four net alpha particles emitted per decay. Targeting 225Ac-drug constructs have potential in the treatment of cancer. Keywords: Actinium-225, 225Ac, alpha particle-emitter, targeted therapy, monoclonal antibody, radioimmunotherapy, nanomaterials, carbon nanotubes, cancer, 225Ac PRODUCTION, Complexing and Chelating Agent Studies

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2174/1874471011104040306

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 47

  1. [1]Milenic DE Brechbiel MW Targeting of radio-isotopes for cancer therapy Cancer Biology & Therapy 3 2004 361 370 14976424
  2. [3]McDevitt MR Sgouros G Finn RD Humm JL Jurcic JG Larson SM Scheinberg DA Radioimmunotherapy with alpha-emitting nuclides European Journal of Nuclear Medicine 25 1998 1341 1351 9724387
  3. [4]Miederer M Scheinberg DA McDevitt MR Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha-particle therapy applications Advanced Drug Delivery Reviews 2008 60 1371 1382 18514364 PMC3630456
  4. [5]Friesen C Glatting G Koop B Schwarz K Morgenstern A Apostolidis C Debatin KM Reske SN Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells Cancer Research 67 2007 1950 1958 17332322
  5. [6]McDevitt MR Ma D Lai LT Simon J Borchardt P Frank RK Wu K Pellegrini V Curcio MJ Miederer M Bander NH Scheinberg DA Tumor therapy with targeted atomic nanogenerators Science 294 2001 1537 1540 11711678
  6. [8]Weast RC 66th Edition of the CRC Handbook of Chemistry and Physics CRC Press, Inc Boca Raton, FL 1985
  7. [11]Koch L Apostolidis C Molinet R Nicolaou G Janssens W Schweikert H Production of Bi-213 and Ac-225, Alpha-Immuno-97 Symposium Karlsruhe, Germany 1997
  8. [13]Apostolidis C Molinet R Rasmussen G Morgenstern A Production of Ac-225 from Th-229 for targeted alpha therapy Analytical chemistry 77 2005 6288 6291 16194090
  9. [14]Boll RA Malkemus D Mirzadeh S Production of actinium-225 for alpha particle mediated radioimmunotherapy Appl Radiat Isot 62 2005 667 679 15763472
  10. [17]McDevitt MR Finn RD Sgouros G Ma D Scheinberg DA An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation Appl Radiat Isot 50 1999 895 904 10214708
  11. [18]Jurcic JG Larson SM Sgouros G McDevitt MR Finn RD Divgi CR Ballangrud AM Hamacher KA Ma D Humm JL Brechbiel MW Molinet R Scheinberg DA Targeted alpha particle immunotherapy for myeloid leukemia Blood 100 2002 1233 1239 12149203
  12. [20]Geerlings MW Kaspersen FM Apostolidis C van der Hout R The feasibility of 225Ac as a source of alpha-particles in radioimmunotherapy Nuclear Medicine Communications 14 1993 121 125 8429990
  13. [23]Apostolidis C Molinet R McGinley J Abbas K Mollenbeck J Morgenstern A Cyclotron production of Ac-225 for targeted alpha therapy Appl Radiat Isot 62 2005 383 387 15607913
  14. [26]Kulikov EV Novgorodov AF Schumann D Hydrolysis of 225Actinium trace quantities J Radioanal Nucl Chem, Letters 164 1992 103 108
  15. [27]McDevitt MR Ma D Simon J Frank RK Scheinberg DA Design and synthesis of 225Ac radioimmunopharmaceuticals Appl Radiat Isot 57 2002 841 847 12406626
  16. [29]Beyer GJ Offord R Kunzi G Aleksandrova Y Ravn U Jahn S Barker J Tengblad O Lindroos M The influence of EDTMP-concentration on the biodistribution of radio-lanthanides and 225-Ac in tumor-bearing mice. The ISOLDE Collaboration Nuclear Medicine and Biology 24 1997 367 372 9290069
  17. [30]Davis IA Glowienka KA Boll RA Deal KA Brechbiel MW Stabin M Bochsler PN Mirzadeh S Kennel SJ Comparison of 225actinium chelates: tissue distribution and radiotoxicity Nuclear Medicine and Biology 26 1999 581 589 10473198
  18. [31]Deal KA Davis IA Mirzadeh S Kennel SJ Brechbiel MW Improved in vivo stability of actinium-225 macrocyclic complexes Journal of Medicinal Chemistry 42 1999 2988 2992 10425108
  19. [32]Kaspersen FM Bos E Doornmalen AV Geerlings MW Apostolidis C Molinet R Cytotoxicity of 213Bi- and 225Ac-immunoconjugates Nuclear Medicine Communications 16 1995 468 476 7675360
  20. [33]Chappell LL Deal KA Dadachova E Brechbiel MW Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications Bioconjugate Chemistry 11 2000 510 519 10898572
  21. [34]Kennel SJ Chappell LL Dadachova K Brechbiel MW Lankford TK Davis IA Stabin M Mirzadeh S Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors Cancer Biotherapy & Radiopharmaceuticals 15 2000 235 244 10941530
  22. [35]Kennel SJ Brechbiel MW Milenic DE Schlom J Mirzadeh S Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49 Cancer Biotherapy & Radiopharmaceuticals 17 2002 219 231 12030116
  23. [38]Miederer M McDevitt MR Borchardt P Bergman I Kramer K Cheung NK Scheinberg DA Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2 Clin Cancer Res 10 2004 6985 6992 15501978
  24. [39]Ballangrud AM Yang WH Palm S Enmon R Borchardt PE Pellegrini VA McDevitt MR Scheinberg DA Sgouros G Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression Clin Cancer Res 10 2004 4489 4497 15240541
  25. [40]Singh Jaggi J Henke E Seshan SV Kappel BJ Chattopadhyay D May C McDevitt MR Nolan D Mittal V Benezra R Scheinberg DA Selective alpha-particle mediated depletion of tumor vasculature with vascular normalization PLoS ONE 2 2007 e267 17342201 PMC1801076
  26. [41]Escorcia FE Henke E McDevitt MR Villa CH Smith-Jones P Blasberg RG Benezra R Scheinberg DA Selective Killing of Tumor Neo-Vasculature Paradoxically Improves Chemotherapy Delivery to Tumors Accepted for publication in Cancer Research 2010 PMC3058681 21045141
  27. [42]Nolan DJ Ciarrocchi A Mellick AS Jaggi JS Bambino K Gupta S Heikamp E McDevitt MR Scheinberg DA Benezra R Mittal V Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization Genes & Development 21 2007 1546 1558 17575055 PMC1891431
  28. [43]Song H Hobbs RF Vajravelu R Huso DL Caroline Esaias C Apostolidis C Morgenstern A Sgouros G Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y Cancer Res 2009 69 23 8941 8948 19920193 PMC2789180
  29. [44]Miederer M Henriksen G Alke A Mossbrugger I Quintanilla-Martinez L Senekowitsch-Schmidtke R Essler M Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors Clin Cancer Res 2008 14 11 3555 3561 18519789
  30. [45]McDevitt MR Chattopadhyay D Kappel BJ Jaggi JS Schiffman SR Antczak C Njardarson JT Brentjens R Scheinberg DA Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes J Nucl Med 48 2007 1180 1189 17607040
  31. [46]Ruggiero A Villa CH Holland JP Sprinkle SR May C Lewis JS Scheinberg DA McDevitt MR Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes International Journal of Nanomedicine 2010 5 783 802 21042424 PMC2962274
  32. [47]McDevitt MR Chattopadhyay D Jaggi JS Finn RD Zanzonico PB Njardarson JT Scheinberg DA Positron-Emission Tomographic (PET) Imaging of Soluble Carbon Nanotubes in Mice PLoS ONE 2 2007 e907 17878942 PMC1975469
  33. [48]Ruggiero A Villa CH Bander E Rey DA Bergkvist M Batt CA Manova-Todorova K Deen WM Scheinberg DA McDevitt MR Paradoxical glomerular filtration of carbon nanotubes Proceedings of the National Academy of Science, USA 2010 107 27 12369 12374 PMC2901461 20566862
  34. [49]Akiyama K Haba H Sueki K Tsukada K Asai M Toyoshima A Nagame Y Katada M Ac-225 Metallofullerene: Toward Ac-225 Nanogenerator in Fullerene Chemistry Letters 2009 38 10 978 979
  35. [52]Sofou S Kappel BJ Jaggi JS McDevitt MR Scheinberg DA Sgouros G Enhanced Retention of the Alpha-particle Emitting Daughters of Actinium-225 by Liposome Carriers Bioconjugate Chemistry 2007 18 6 2061 2067 17935286 PMC2582153
  36. [53]Chang MY Seideman J Sofou S Enhanced loading efficiency and retention of 225Ac in rigid liposomes for potential targeted therapy of micrometastases Bioconjug Chem 2008 19 6 1274 1282 18505278
  37. [54]Sofou S Enmon R Palm S Kappel B Zanzonico P McDevitt MR Scheinberg DA Sgouros G Large anti-HER2/neu liposomes for potential targeted intraperitoneal therapy of micrometastatic cancer J Liposome Res 2010 20 4 330 340 20070139 PMC3172685
  38. [56]Ruggiero A Holland JP Lewis JS Grimm J Cerenkov Luminescence Imaging of Medical Isotopes J Nucl Med 2010 51 1123 1130 20554722 PMC3068779
  39. [57]Jaggi JS Kappel BJ McDevitt MR Sgouros G Flombaum CD Cabassa C Scheinberg DA Efforts to control the errant products of a targeted in vivo generator Cancer Research 65 2005 4888 4895 15930310
  40. [59]Yuan RR Wong P McDevitt MR Doubrovina E Leiner I Bornmann W O’Reilly R Pamer EG Scheinberg DA Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers Blood 2004 104 2397 2402 15217835
  41. [60]Jaggi JS Seshan SV McDevitt MR LaPerle K Sgouros G Scheinberg DA Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters J Am Soc Nephrol 16 2005 2677 2689 15987754
  42. [61]Jaggi JS Seshan SV McDevitt MR Sgouros G Hyjek E Scheinberg DA Mitigation of radiation nephropathy after internal alpha-particle irradiation of kidneys International Journal of Radiation Oncology, Biology, Physics 64 2006 1503 1512 16503385
  43. [62]Sgouros G Roeske JC McDevitt MR Palm S Allen BJ Fisher DR Brill AB Song H Howell RW Akabani G MIRD Pamphlet No. 22 - Radiobiology and Dosimetry of Alpha-Particle Emitters for Targeted Radionuclide Therapy PMC5680544 20080889
  44. [63]Sgouros G Roeske JC McDevitt MR Palm S Allen BJ Fisher DR Brill AB Song H Howell RW Akabani G MIRD Pamphlet No. 22 (Abridged):Radiobiology and Dosimetry of a-Particle Emitters for Targeted Radionuclide Therapy J Nucl Med 2010 51 311 328 1 105 20080889 PMC5680544
  45. [64]Hamacher KA Sgouros G A schema for estimating absorbed dose to organs following the administration of radionuclides with multiple unstable daughters: a matrix approach Medical Physics 26 1999 2526 2528 10619234
  46. [66]Hamacher KA Sgouros G Theoretical estimation of absorbed dose to organs in radioimmunotherapy using radionuclides with multiple unstable daughters Medical Physics 28 2001 1857 1874 11585217
  47. [69]Rosenblat TL McDevitt MR Mulford DA Pandit-Taskar N Divgi CR Panageas KS Mark L Heaney ML Chanel S Morgenstern A Sgouros G Larson SM Scheinberg DA Jurcic JG Sequential Cytarabine and Alpha-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia Clin Can Res 2010 16 21 5303 5311 PMC2970691 20858843

Cited by

Sorted by citations

Related

Authors
A. Scheinberg, D., & R. McDevitt, M.
Venue
Current Radiopharmaceuticalse
Publisher
Bentham Science Publishers Ltd.
Published
2011-10-01
Volume
4
Issue
4
Pages
306-320
ISSN
1874-4710 (ISSN-L)
DOI
10.2174/1874471011104040306
PMC
PMC5565267
OpenAlex
W2316959840
Cited by
176
References
9
Citations by year
2026: 10 · 2025: 18 · 2024: 20 · 2023: 23 · 2022: 16 · 2021: 26 · 2020: 19 · 2019: 8 · 2018: 7 · 2017: 9 · 2016: 6 · 2015: 2 · 2014: 8 · 2013: 1 · 2012: 3
FWCI
2.94
Type
journal article
Language
en
Open access
Locations
  • Current Radiopharmaceuticals (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Cancer Institute (P30CA008748)
Topics
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Chemical Reactions and Isotopes
  • Physical Sciences › Physics and Astronomy › Nuclear and High Energy Physics › Nuclear physics research studies
Keywords
actinium-225, alpha-emitting radionuclides, targeted alpha therapy, radioimmunotherapy, monoclonal antibodies, carbon nanotubes, acute myeloid leukemia, linear energy transfer, chelating agents, cancer radiotherapy
MeSH terms
Actinium, Alpha Particles, Animals, Antibodies, Monoclonal, Clinical Trials as Topic, Humans, Liposomes, Neoplasms, Radiotherapy Dosage, Radioimmunotherapy, Radiopharmaceuticals, Models, Animal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review